MEF2D and gastric cancer: In particular, miR-200 targeted B-catenin, and miR-19 inhibited myocyte enhancer factor 2D (MEF2D) to block the Wnt pathway, while miR-133a-5p targeted TCF (which enhanced the transcription of oncogenes), thereby stopping cell proliferation in gastric cancer [145].